Thursday, January 17, 2019

Lifestyle Intervention Associated with Higher Disease-free Survival Rates in Breast Cancer

According to results of a study presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in San Antonio, TX, survivors of early-stage breast cancer who participated in a lifestyle intervention on healthy habits lost weight and experienced higher rates of disease-free survival if they completed the program. This study was funded, in part, by Chugai, Glaxo...

Exercise may Improve Cardiovascular Function During Adjuvant Breast Cancer Treatment

According to results of the Energy Balance and Breast Cancer Aspect (EBBA)-II trial (NCT02240836) , sponsored by the Norwegian Research Council, Norwegian Health Authority, Oslo University Hospital, St Olavs Hospital, and Active Against Cancer – Gjensidige Foundation, presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018, women who underwent a supervised program of cardiovascular exercise...

Oxybutynin Improved Quality of Life for Breast Cancer Survivors

Treatment with oxybutynin chloride (Ditropan XL®; Janssen Pharmaceuticals) helped reduce the frequency and intensity of hot flashes for women who could not take hormone replacement, including breast cancer survivors, according to results of a study presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in San Antonio, TX. the study was funded by the Breast...

Type of Surgery May affect Health Related Quality of Life for Young Breast Cancer Survivors

Results from a study funded by the Agency for Healthcare Research and Quality, Susan G. Komen, the Breast Cancer Research Foundation, and The Pink Agenda and presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in San Antonio, TX, confirm that younger breast cancer patients who underwent mastectomy reported lower breast satisfaction and poorer psychosocial...

No Significant Improvement in Early-stage TNBC Patients Treated with Adjuvant Capecitabine

Treating patients who had early-stage triple-negative breast cancer (TNBC) with the chemotherapeutic agent capecitabine (Xeloda®; Genentech/Roche) after they completed surgery and standard chemotherapy did not significantly improve disease-free or overall survival compared with observation, according to data from the randomized, phase III GEICAM/CIBOMA clinical trial presented at the 2018 San Antonio Breast Cancer Symposium (SABCS), held in San Antonio,...

The Promise of CAR T-Cell Therapy

Chimeric  Antigen T-cell therapy or CAR T-cell therapy is one of the most promising types of immunotherapy.  Early results as well as experiences with approved CAR T-cell therapies have shown the potential to induce sustained remissions in patients with refractory disease. Because the majority of adult B-cell malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, and non–Hodgkin's lymphoma, remain,...

KATHERINE Trial: Trastuzumab Emtansine Reduces Risk of Invasive Recurrence of Breast Cancer by 50%

Results from the Phase III KATHERINE Clinical Trial (NCT01772472), supported by F. Hoffmann Genentech/Roche and presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in the Henry B. González Convention Center located along the banks of the River Walk in Downtown San Antonio, Texas, shows that substituting (ado-) trastuzumab emtansine (T-DM1, Kadcyla®; Genentech/Roche) for adjuvant...

Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma Shows Promise

Initial safety data from an ongoing proof-of-concept trial of JCARH125, an investigational BCMA-targeting CAR T being developed by Juno Therapeutics/Celgene Corporation) in patients with relapsed/refractory multiple myeloma, were  presented by Sham Mailankody, MBBS, in an oral presentation at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA (Abstract #957). The data from 44 patients...

MEDALIST Trial in Patients with Myelodysplastic Syndromes Shows Statistical Benefit

Data from the pivotal phase III MEDALIST trial (NCT02631070) shows that treatment with luspatercept (ACE-536), an investigational drug for the treatment of patients with myelodysplastic syndromes, resulted in statistically significant increased red blood cell transfusion independence compared to placebo. Based on the these results Celgene and Acceleron Pharma, the developers of the drug, are planning regulatory submissions in the...

The Future of Medicine is Bright: Personalized Medicine, Predictive Analytics and Big Data

Modern medicine is to change dramatically. Over the past 200 years medicine has seen extraordinary developments and advances. From microbiology to the sequencing of the human genome, the advent of CRISPR–Cas genome editing to potentially treat disease and advance drug discovery and development, as well as a better understanding of underlying biology of cancer and hematological disease, and the availability...

Related articles